These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
585 related articles for article (PubMed ID: 22027887)
1. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. Lin H; Faraklas I; Saffle J; Cochran A J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887 [TBL] [Abstract][Full Text] [Related]
2. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050 [TBL] [Abstract][Full Text] [Related]
3. Enoxaparin and antifactor Xa levels in acute burn patients. Lin H; Faraklas I; Cochran A; Saffle J J Burn Care Res; 2011; 32(1):1-5. PubMed ID: 21124231 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of an enoxaparin dosing calculator using burn size and weight. Faraklas I; Ghanem M; Brown A; Cochran A J Burn Care Res; 2013; 34(6):621-7. PubMed ID: 24043245 [TBL] [Abstract][Full Text] [Related]
5. Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism. Yogaratnam D; Smith BS; Angood PB; Gandhi PJ Pharmacotherapy; 2004 Dec; 24(12):1793-9. PubMed ID: 15585445 [TBL] [Abstract][Full Text] [Related]
6. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080 [TBL] [Abstract][Full Text] [Related]
7. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998 [TBL] [Abstract][Full Text] [Related]
8. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety. Lachish T; Rudensky B; Slotki I; Zevin S Pharmacotherapy; 2007 Oct; 27(10):1347-52. PubMed ID: 17896889 [TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved. Nunez JM; Becher RD; Rebo GJ; Farrah JP; Borgerding EM; Stirparo JJ; Lauer C; Kilgo P; Miller PR Am Surg; 2015 Jun; 81(6):605-9. PubMed ID: 26031274 [TBL] [Abstract][Full Text] [Related]
10. Relation of antifactor-Xa peak levels and venous thromboembolism after trauma. Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Martin AG; Lineen EB; Namias N; Schulman CI; Proctor KG J Trauma Acute Care Surg; 2017 Dec; 83(6):1102-1107. PubMed ID: 29190255 [TBL] [Abstract][Full Text] [Related]
11. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965 [TBL] [Abstract][Full Text] [Related]
12. The EFFORT trial: Preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial. Steele KE; Canner J; Prokopowicz G; Verde F; Beselman A; Wyse R; Chen J; Streiff M; Magnuson T; Lidor A; Schweitzer M Surg Obes Relat Dis; 2015; 11(3):672-83. PubMed ID: 25620436 [TBL] [Abstract][Full Text] [Related]
13. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer? Kopelman TR; O'Neill PJ; Pieri PG; Salomone JP; Hall ST; Quan A; Wells JR; Pressman MS Am J Surg; 2013 Dec; 206(6):911-5; discussion 915-6. PubMed ID: 24296098 [TBL] [Abstract][Full Text] [Related]
14. Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5? Yildirim T; Kocak T; Buyukasik Y; Yilmaz R; Altun B; Erdem Y; Arici M Blood Coagul Fibrinolysis; 2012 Dec; 23(8):700-4. PubMed ID: 23135378 [TBL] [Abstract][Full Text] [Related]
15. Increased enoxaparin dosing is required for obese children. Lewis TV; Johnson PN; Nebbia AM; Dunlap M Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026 [TBL] [Abstract][Full Text] [Related]
16. Enoxaparin and antifactor Xa levels in pediatric acute burn patients. Brown A; Faraklas I; Ghanem M; Cochran A J Burn Care Res; 2013; 34(6):628-32. PubMed ID: 24043233 [TBL] [Abstract][Full Text] [Related]
17. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. Van PY; Cho SD; Underwood SJ; Morris MS; Watters JM; Schreiber MA J Trauma; 2009 Jun; 66(6):1509-15; discussion 1515-7. PubMed ID: 19509608 [TBL] [Abstract][Full Text] [Related]
18. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498 [TBL] [Abstract][Full Text] [Related]
19. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610 [TBL] [Abstract][Full Text] [Related]